H2-Histamine Receptor Antagonists: Examples and Clinical Context
Primary H2-Receptor Antagonist Medications
The four main H2-histamine receptor antagonists available are cimetidine, ranitidine, famotidine, and nizatidine. 1
Specific Agents with Dosing
Cimetidine: 30–40 mg/kg/day divided in 4 doses (pediatric); 300 mg three-four times daily (adult equivalent dosing) 1
Ranitidine: 5–10 mg/kg/day divided in 2-3 doses (pediatric); 150 mg twice daily (adult equivalent dosing) 1
Famotidine: 1 mg/kg/day divided in 2 doses (pediatric); 20 mg twice daily (adult equivalent dosing) 1
Nizatidine: 10 mg/kg/day divided in 2 doses (pediatric); 150 mg twice daily (adult equivalent dosing) 1
Mechanism of Action
H2-receptor antagonists decrease gastric acid secretion by competitively inhibiting the histamine-2 receptor on gastric parietal cells. 1, 2 These agents exhibit classical competitive drug-receptor interactions with rapid onset of action—gastric pH begins increasing within 30 minutes of administration, reaching peak plasma concentrations at 2.5 hours, with acid-inhibiting effects lasting approximately 6 hours. 1, 3
Relative Potency Differences
Famotidine is the most potent H2-receptor antagonist, being 20-50 times more potent than cimetidine and 6-10 times more potent than ranitidine. 3 This intrinsic potency difference translates to lower effective plasma concentrations required for famotidine compared to other agents in this class. 3, 4
Important Clinical Limitations
Tachyphylaxis Development
A critical limitation is that fairly rapid tachyphylaxis develops within 6 weeks of initiating H2-receptor antagonist treatment, substantially limiting their potential for long-term use. 1 This tolerance phenomenon reduces their clinical effectiveness over time and represents a major disadvantage compared to proton pump inhibitors.
Comparative Efficacy
H2-receptor antagonists have been shown to be less effective than proton pump inhibitors in both symptom relief and healing rates of erosive esophagitis. 1 Standard doses of H2-receptor antagonists reduce the risk of duodenal ulcers but not gastric ulcers in NSAID users, though double-dose regimens show efficacy for both. 1
Drug-Specific Adverse Effects
Cimetidine has specifically been linked to increased risk of liver disease and gynecomastia due to its antiandrogenic activity, and these associations may be generalizable to other H2-receptor antagonists. 1, 5 Cimetidine and ranitidine also inhibit the hepatic cytochrome P-450 enzyme system, leading to clinically significant drug interactions with warfarin and theophylline that require monitoring. 5 In contrast, famotidine and nizatidine do not significantly bind to cytochrome P-450 and offer a definite advantage regarding drug interaction potential. 4, 5
Current Clinical Role
H2-receptor antagonists are now primarily used for faster onset of action when needed and for control of nocturnal breakthrough reflux in patients already on proton pump inhibitor therapy. 1 Their role has diminished as first-line therapy given the superior efficacy of proton pump inhibitors and the development of tachyphylaxis with H2-receptor antagonists. 1